Knockdown of Alpha-1 Antitrypsin with antisense oligonucleotide does not exacerbate smoke induced lung injury.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 24 07 2020
accepted: 12 01 2021
entrez: 4 2 2021
pubmed: 5 2 2021
medline: 24 7 2021
Statut: epublish

Résumé

Alpha-1 Antitrypsin (AAT) is a serum protease inhibitor that regulates increased lung protease production induced by cigarette smoking. Mutations in the Serpina1 gene cause AAT to form hepatoxic polymers, which can lead to reduced availability for the protein's primary function and severe liver disease. An AAT antisense oligonucleotide (ASO) was previously identified to be beneficial for the AATD liver disease by blocking the mutated AAT transcripts. Here we hypothesized that knockdown of AAT aggravates murine lung injury during smoke exposure and acute exacerbations of chronic obstructive pulmonary disease (COPD). C57BL/6J mice were randomly divided into 4 groups each for the smoking and smoke-flu injury models. The ASO and control (No-ASO) were injected subcutaneously starting with smoking or four days prior to influenza infection and then injected weekly at 50 mg/kg body weight. ASO treatment during a 3-month smoke exposure significantly decreased the serum and lung AAT expression, resulting in increased Cela1 expression and elastase activity. However, despite the decrease in AAT, neither the inflammatory cell counts in the bronchoalveolar lavage fluid (BALF) nor the lung structural changes were significantly worsened by ASO treatment. We observed significant differences in inflammation and emphysema due to smoke exposure, but did not observe an ASO treatment effect. Similarly, with the smoke-flu model, differences were only observed between smoke-flu and room air controls, but not as a result of ASO treatment. Off-target effects or compensatory mechanisms may account for this finding. Alternatively, the reduction of AAT with ASO treatment, while sufficient to protect from liver injury, may not be robust enough to lead to lung injury. The results also suggest that previously described AAT ASO treatment for AAT mutation related liver disease may attenuate hepatic injury without being detrimental to the lungs. These potential mechanisms need to be further investigated in order to fully understand the impact of AAT inhibition on protease-antiprotease imbalance in the murine smoke exposure model.

Identifiants

pubmed: 33539438
doi: 10.1371/journal.pone.0246040
pii: PONE-D-20-23075
pmc: PMC7861354
doi:

Substances chimiques

Oligonucleotides, Antisense 0
Serpina1a protein, mouse 0
alpha 1-Antitrypsin 0
CELA1 protein, mouse EC 3.4.21.36
Pancreatic Elastase EC 3.4.21.36

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0246040

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL086936
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL120826
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Chest. 1986 Mar;89(3):370-3
pubmed: 3485034
Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):2788-2793
pubmed: 29453277
Am J Respir Cell Mol Biol. 2018 Aug;59(2):167-178
pubmed: 29420065
Ann Am Thorac Soc. 2016 Aug;13 Suppl 4:S297-304
pubmed: 27564664
Methods Mol Biol. 2017;1639:9-19
pubmed: 28752442
Respirology. 2010 Apr;15(3):536-42
pubmed: 20415983
J Pediatr. 2013 Aug;163(2):320-6
pubmed: 23664631
Semin Respir Crit Care Med. 2005 Apr;26(2):142-53
pubmed: 16088433
Am J Physiol Lung Cell Mol Physiol. 2014 Jun 15;306(12):L1104-16
pubmed: 24793170
Am J Respir Crit Care Med. 2003 Oct 1;168(7):818-900
pubmed: 14522813
Adv Drug Deliv Rev. 2015 Jun 29;87:90-103
pubmed: 25797014
Rare Dis. 2014 Mar 12;2:e28511
pubmed: 25054094
Chronic Obstr Pulm Dis. 2016 Nov 18;4(1):34-44
pubmed: 28848909
Respir Res. 2015 Jul 15;16:85
pubmed: 26169056
Clin Chest Med. 2014 Mar;35(1):157-63
pubmed: 24507843
COPD. 2015 May;12 Suppl 1:58-62
pubmed: 25938294
Agents Actions Suppl. 1993;40:3-12
pubmed: 8480553
BMC Pulm Med. 2013 Jun 04;13:36
pubmed: 23734748
Am J Respir Cell Mol Biol. 2016 Nov;55(5):708-715
pubmed: 27373990
Am J Respir Crit Care Med. 2016 Apr 15;193(8):825-34
pubmed: 26599602
Curr Mol Med. 2012 Aug;12(7):807-14
pubmed: 22697347
Lung. 1990;168 Suppl:552-64
pubmed: 2117164
Pneumonol Alergol Pol. 2011;79(3):207-14
pubmed: 21509733

Auteurs

Kyle Stearns (K)

College of Physicians and Surgeons, Columbia University Medical Center, New York, New York, United States of America.

Monica Goldklang (M)

College of Physicians and Surgeons, Columbia University Medical Center, New York, New York, United States of America.

Rui Xiao (R)

College of Physicians and Surgeons, Columbia University Medical Center, New York, New York, United States of America.

Tina Zelonina (T)

College of Physicians and Surgeons, Columbia University Medical Center, New York, New York, United States of America.

Keith Blomenkamp (K)

Department of Biochemistry and Molecular Biology, Saint Louis University. St. Louis, Missouri, United States of America.

Jeffery Teckman (J)

Department of Biochemistry and Molecular Biology, Saint Louis University. St. Louis, Missouri, United States of America.

Jeanine M D'Armiento (JM)

College of Physicians and Surgeons, Columbia University Medical Center, New York, New York, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH